BNTX BioNTech SE

BioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development Program

BioNTech to Hold Press Conference to Provide an Update on COVID-19 Vaccine Development Program

Mainz, Germany, December 21, 2020 (GLOBE NEWSWIRE) – (Nasdaq: BNTX, “BioNTech” or “the Company”) will hold a press conference including a video webcast on Tuesday, December 22, 2020, to provide an update on the status of the COVID-19 vaccine development program of its lead vaccine candidate BNT162b2. The event will be held virtual and in English:

International press conference at 09.00am CET / 03.00am ET

Please register .

Interested journalists may dial in 10-15 minutes before the conference starts. They will be able to submit questions via an online tool. The press conference will be virtual only.

Participants may also access the press conference, including the video webcast, on under "Events & Presentations" in the Investor & Media section of the website. A recording of the press conference will be available on the same day. Additional media materials including images and videos can be accessed through the following link: .

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

For more information, please visit .

BioNTech Contacts

Media Relations

Jasmina Alatovic

Director External Communications

+49 (0)89 62 81 75 46

Investor Relations

Sylke Maas, Ph.D.

VP Investor Relations & Business Strategy

+49 (0)6131 9084 1074

 



EN
21/12/2020

Underlying

BNTXBioNTech SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioNTech SE

 PRESS RELEASE
Free
BNTX BIONTECH SE

BioNTech veranstaltet am 1. Oktober 2025 zweiten „AI Day“ als eine Aus...

BioNTech veranstaltet am 1. Oktober 2025 zweiten „AI Day“ als eine Ausgabe der „Innovation Series“   MAINZ, Deutschland, 23. September 2025 (GLOBE NEWSWIRE) --  (Nasdaq: BNTX, „BioNTech“) richtet zusammen mit ihrem Tochterunternehmen für künstliche Intelligenz (artificial intelligence, „AI“), („InstaDeep“), am Dienstag, den 1. Oktober 2025 um 15:00 Uhr MESZ (09:00 Uhr EDT) ihren zweiten „AI Day“ aus, eine Ausgabe von BioNTechs „Innovation Series“ in London, Vereinigtes Königreich. Die Veranstaltung gibt einen Überblick über die Strategie und die Fähigkeiten von BioNTech im Bereich AI und...

September 23, 2025 1 EN
 PRESS RELEASE
Free
BNTX BIONTECH SE

BioNTech to Host Second AI Day as an Edition of Its Innovation Series ...

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025 MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company (“InstaDeep”), will host its second AI Day, an edition of BioNTech’s “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Wednesday, October 1, 2025, in London, United Kingdom. The event will provide an overview of BioNTech’s AI strategy and capabilities, and the application of AI in BioNTech’s pipeline and internal processes. The live webcast of the event will...

September 23, 2025 1 EN
 PRESS RELEASE
Free
BNTX BIONTECH SE

Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studi...

Erste Zwischenergebnisse aus BioNTechs und BMS‘ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig (BNT327/BMS986545) zeigen ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem kleinzelligem Lungenkrebs Daten zur Kombination des bispezifischen PD-L1xVEGF-A-Antikörper-Kandidaten Pumitamig (BNT327/BMS986545) mit Chemotherapie zeigen weiterhin ermutigende Anti-Tumor-Aktivitäten bei Patientinnen und Patienten mit kleinzelligem Lungenkrebs im fortgeschrittenen Stadium (extensive-stage small cell lung cancer, „ES-SCLC“) und untermauern das Potenzial von Pumita...

September 8, 2025 1 EN
 PRESS RELEASE
Free
BNTX BIONTECH SE

First Disclosure of Global Interim Phase 2 Data for BioNTech and Brist...

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), expanding evidence for its potential to set a new standard of care in first-line ES-SCLC and beyondGlobal interim Phase 2 data showed a 76.3% confirmed object...

September 8, 2025 1 EN
 PRESS RELEASE
Free
BNTX BIONTECH SE

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults...

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1Shipping of the LP.8.1-adapted vaccine will begin immediately to ensure robust supply and rapid access of this season’s vaccine in pharmacies, hospitals, and clinics across the country NEW YORK and MAINZ, GERMANY, AUGUST 27, 2025 — (NYSE: PFE, “Pfizer”) and (Nasdaq: BNTX, “BioNTech”) ...

August 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch